Astellas Pharma Inc. (ALPMY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Tokyo, Japan. Der aktuelle CEO ist Naoki Okamura.
ALPMY hat IPO-Datum 2009-12-29, 14,754 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $28.7B.
Astellas Pharma Inc. is a Tokyo-based pharmaceutical company founded in 1923 that engages in the manufacture, marketing, and distribution of prescription drugs across major global markets. The company maintains a diverse portfolio spanning oncology, urology, immunology, and infectious disease, with notable products including XTANDI for prostate cancer, XOSPATA for acute myeloid leukemia, PADCEV for urothelial cancer, and immunosuppressants Prograf and Advagraf used in organ transplantation. Beyond its marketed medicines, Astellas actively pursues innovation through strategic collaborations with leading research institutions including Harvard University and biopharmaceutical companies such as Merck, Cytokinetics, and Actinium Pharmaceuticals, with particular focus on cell therapy, targeted radiotherapy, and epigenetic therapies. The company's pipeline and research initiatives reflect its commitment to addressing significant unmet medical needs in oncology, nephrology, and other therapeutic areas.
